Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication March 5, 2019
- Accepted for publication March 19, 2019
- Published online June 3, 2019.
Article Versions
- previous version (April 6, 2019 - 09:28).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.
Author Information
- Clemens Kratochwil*,1,
- Paul Flechsig*,1,2,
- Thomas Lindner1,
- Labidi Abderrahim1,
- Annette Altmann1,3,
- Walter Mier1,
- Sebastian Adeberg4,5,
- Hendrik Rathke1,
- Manuel Röhrich1,
- Hauke Winter2,6,
- Peter K. Plinkert7,
- Frederik Marme8,9,
- Matthias Lang10,
- Hans-Ulrich Kauczor2,11,
- Dirk Jäger12,13,
- Jürgen Debus4,5,14,
- Uwe Haberkorn1–3 and
- Frederik L. Giesel1
- 1Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany
- 2Translational Lung Research Center Heidelberg, German Center for Lung Research, Heidelberg, Germany
- 3Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany
- 4Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany
- 5Heidelberg Institute for Radiation Oncology, Heidelberg, Germany
- 6Department of Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany
- 7Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Heidelberg, Heidelberg, Germany
- 8Department Obstetrics and Gynecology, University Hospital Heidelberg, Heidelberg, Germany
- 9Department Obstetrics and Gynecology, University Hospital Mannheim, Mannheim, Germany
- 10Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
- 11Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
- 12Department of Medical Oncology and Internal Medicine VI, National Center for Tumor Diseases, University Hospital Heidelberg, Germany
- 13Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Heidelberg, Germany; and
- 14Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany
- For correspondence or reprints contact: Clemens Kratochwil, Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. E-mail: clemens.kratochwil{at}med.uni-heidelberg.de
↵* Contributed equally to this work.
Cited By...
Article usage
68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer
Jump to section
Related Articles
Cited By...
- Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy
- Immunotherapy with immunocytokines and PD-1 blockade enhances the anticancer activity of small molecule-drug conjugates targeting carbonic anhydrase IX
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor
- The Future of Nuclear Medicine, Molecular Imaging, and Theranostics
- Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents
- Design and Development of 99mTc-Labeled FAPI Tracers for SPECT Imaging and 188Re Therapy
- Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography
- The Role of 68Ga-FAPI PET/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience
- Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET Imaging in Cancer Patients
- The Future of Nuclear Medicine Depends on the Quality of Its Research: Researchers at the University of Heidelberg Receive the Award for Best Article of the Year
- High-resolution positron emission microscopy of patient-derived tumor organoids
- Reversibility of 68Ga-FAPI-2 Trapping Might Prove an Asset for PET Quantitative Imaging
- Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models
- FAP: The Next Billion Dollar Nuclear Theranostics Target?
- A Conversation Between Uwe Haberkorn and Johannes Czernin